A Phase 4 interventional study of Estroprogestinic therapy (Etinil-estradiol/levonorgestre) and Gonadotropin-releasing hormone agonist (Leuprorelin acetate) in Amenorrhea, Endometriosis and Quality of Life, sponsored by University of Cagliari. Status unknown at 1 site in Italy. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-02-04.
Sponsored by University of Cagliari · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the impact on quality of life, psychological health, sexuality and chronic pain of therapies which determine amenorrhea in symptomatic women with endometriosis, through the administration of self reported questionnaires. Amenorrhea in the first group is caused by balanced assumption of estroprogestins, in the second group is caused by GnRHa-induced hypoestrogenism.
80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.
This study's planned enrollment of 50 is close to the median of 54 across 49 interventional studies indexed under Amenorrhea.
Browse Amenorrhea studies →University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
Drug: Estroprogestinic therapy (Etinil-estradiol/levonorgestre)
Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
Drug: Gonadotropin-releasing hormone agonist (Leuprorelin acetate) · Drug: Add back therapy 1 (tibolone) · Drug: Add back therapy 2 (calcium carbonate/colecalciferol)
Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
Leuprorelin acetate (3,75 mg/2 ml)/month
tibolone 5 mg/die
calcium carbonate/colecalciferol (500mg/400UI)/die
Quality of life (self reported questionnaires)
This outcome will be evaluated through self reported questionnaires
Time frame: 180 days
Sexual health (self reported questionnaires)
This outcome will be evaluated through self reported questionnaires
Time frame: 180 days
Psychological impact (self reported questionnaires)
This outcome will be evaluated through self reported questionnaires
Time frame: 180 days
Start is estimated for Jun 2021; primary completion for Dec 2021, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gonadotropin-releasing Hormone Analog · Tibolone
University of Cagliari